SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER

描述（由申请人提供）：本申请代表了来自丹娜-法伯/哈佛癌症中心（DF/HCC）胃肠道（GI）恶性肿瘤项目的胃肠道癌症研究卓越专业项目（SPORE）的竞争性更新。DF/HCC孢子在胃肠道肿瘤中的主要目标是将生物学和技术进步转化为预防、诊断、预后预测和胃肠道恶性肿瘤治疗方面的改进。GI癌中的DF/HCC孢子包括来自所有哈佛附属医院和机构的研究人员：丹娜-法伯癌症研究所、布里格姆妇女医院、马萨诸塞州总医院、贝斯以色列女执事医疗中心、波士顿儿童医院、哈佛医学院、哈佛公共卫生学院和布罗德研究所。拟开展5个主要项目：1)Barrett食管高级别发育不良分子影像学检测；2)明确维生素D在结直肠癌发生和癌症生存中的作用；3)寻找kras突变型结直肠癌的新治疗策略；4)克服braf突变型结直肠癌对RAF抑制的抗性；5)克服GIST对KIT/PDGFRA抑制的抗性。这些项目将通过三个核心进行整合：1)行政、评估和规划；2)组织病理学；3)生物统计学与生物信息学。《孢子》申请概述了一个发展项目计划，其中包括新项目的选择计划，并记录了18个在当前资金周期中得到支持的高度创新和富有成效的发展项目。我们还包括一个职业发展计划，该计划概述了识别和支持GI癌症领域有才华的年轻研究人员的机制，并报告了我们在当前资助周期内支持和指导15名年轻研究人员的成功情况。本申请中提出的项目和核心与现有的DF/HCC核心资源高度整合，并涉及与其他现有孢子和癌症中心的研究人员的关键合作。这项针对DF/HCC的GI SPORE的更新将把哈佛大学在基础、转化和临床科学方面的领先研究人员结合到一个项目中，该项目具有在GI癌症的诊断、治疗和预防方面产生有意义的进展所需要的重点和协调。

DESCRIPTION (provided by applicant): This application represents the competitive renewal of a Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer originating from the Gastrointestinal (GI) Malignancies Program of the Dana-Farber/Harvard Cancer Center (DF/HCC). The main goal of the DF/HCC SPORE in GI Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of gastrointestinal malignancies. The DF/HCC SPORE in GI Cancer includes researchers from all Harvard-affiliated hospitals and institutions: the Dana-Farber Cancer Institute, the Brigham and Women's Hospital, the Massachusetts General Hospital, the Beth Israel Deaconess Medical Center, Children's Hospital of Boston, Harvard Medical School, Harvard School of Public Health, and Broad Institute. Five major projects are proposed including: 1) Molecular imaging for detection of high grade dysplasia in Barrett's Esophagus; 2) Defining the role of vitamin D in colorectal carcinogenesis and cancer survival; 3) Identifying novel therapeutic strategies for KRAS-mutant colorectal cancer; 4) Overcoming resistance to RAF inhibition in BRAF-mutant colorectal cancer; and 5) Overcoming Resistance to KIT/PDGFRA Inhibition in GIST. These projects will be integrated by three cores: 1) Administration, Evaluation & Planning; 2) Tissue & Pathology; and 3) Biostatistics & Bioinformatics. The SPORE application outlines a Developmental Projects Program that includes a plan of selection of new projects and documents 18 highly innovative and productive developmental projects that have been supported during the current funding cycle. We also include a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in GI cancer and report on our success in supporting and mentoring 15 young investigators during the current funding cycle. The projects and cores proposed in this application are highly integrated with present DF/HCC core resources, and involve key collaborations with investigators from other existing SPOREs and cancer centers. The renewal of this GI SPORE at DF/HCC will combine leading Harvard researchers in basic, translational, and clinical sciences into a program that has the focus and coordination required to produce meaningful advances in the diagnosis, treatment, and prevention of GI cancers.